Preventing recurrence of Clostridium difficile infection (CDI)
New data presented today at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017, demonstrate benefits of extended-pulsed fidaxomicin (EPFX), compared to standard vancomycin.
Data from the EXTEND study show that EPFX provides a superior rate of sustained clinical cure at 30 days following treatment compared to standard vancomycin. At 40 days, recurrence rates were also found to be almost 10 times lower in patients treated with EPFX compared with standard vancomycin. EPFX is currently not an approved dosing regimen.
“The results of the study show at 30 days after end of treatment (i.e. day 55 for extended fidaxomicin (EPFX) and day 40 for vancomycin), recurrence occurred in 4.0% and 16.8% of patients receiving EPFX and vancomycin, respectively”, commented study author Professor Benoit Guery, Infectious Diseases Services, University Hospital of Lausanne. “The EXTEND study shows superiority of extended fidaxomicin over vancomycin1 and importantly this result is obtained with the same number of tablets and therefore does not change the cost and clearly improves the cost-efficacy ratio.” The extended-pulsed fidaxomicin regimen means that patients receive the same number of tablets as the standard licensed course of fidaxomicin (one tablet administered twice daily for 10 days), but over a longer period of time.
A randomised, controlled, open-label study, the EXTEND trial is the first multicentre study of clinical outcomes for EPFX and was conducted in hospitals in 22 European countries.
Dr. Andreas Karas, Senior Medical Director, Astellas Pharma EMEA, commented, “Recurrence of disease is one of the largest ongoing unmet needs of CDI treatment and the EXTEND study was designed to specifically get this as low as possible by minimising the impact on the gut flora by using a pulsed dosing regimen. Getting recurrence to levels as low as shown in this trial is a positive outcome for patients but also for health systems that bear the economic burden”.
Economic analyses of the EXTEND study data indicate that EPFX is a cost-effective treatment strategy compared with standard vancomycin. This finding was driven by the reduction in hospitalisation costs, resulting from the reduced recurrence rates associated with EPFX.
Fidaxomicin is indicated in adults for the treatment of CDI. The recommended dose is one 200mg tablet administered twice daily for 10 days. Extended-pulsed regimen with fidaxomicin is not currently approved.
You may be interested
The first Aegean Hawk S-70 helicopter was delivered to the Hellenic Navy by AeroservicesPanos - May 07, 2021
The first upgraded Aegean Hawk S-70 helicopter was delivered to the Hellenic Navy today, Thursday 6 May. The work on…
Foreigners looking to buy Greek property amid Covid-19 pandemicPanos - May 07, 2021
Despite the pandemic, the demand for a permanent holiday home in selected destinations in Greece by foreigners is on the…
Greek Taxisnet services not available for citizens over weekendPanos - May 07, 2021
Online services on the Taxisnet platform system will not be available to taxpayers over the weekend due to scheduled upgrading.…